Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 116, Issue 25, Pages 12442-12451Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1816410116
Keywords
breast cancer; mammary tumor; JAK; STAT; inflammation
Categories
Funding
- National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000114]
- NIH/National Institute of Allergy and Infectious Diseases [T32AI007313]
- NIH/National Cancer Institute [F31CA220746, T32CA009138, R01CA215052]
- NIH/Eunice Kennedy Shriver National Institute of Child Health and Development [R01HD095858]
- Department of Defense [W81XWH-16-1-0034]
Ask authors/readers for more resources
Tumor-associated macrophages contribute to tumor progression and therapeutic resistance in breast cancer. Within the tumor microenvironment, tumor-derived factors activate pathways that modulate macrophage function. Using in vitro and in vivo models, we find that tumor-derived factors induce activation of the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway in macrophages. We also demonstrate that loss of STAT3 in myeloid cells leads to enhanced mammary tumorigenesis. Further studies show that macrophages contribute to resistance of mammary tumors to the JAK/STAT inhibitor ruxolitinib in vivo and that ruxolitinib-treated macrophages produce soluble factors that promote resistance of tumor cells to JAK inhibition in vitro. Finally, we demonstrate that STAT3 deletion and JAK/STAT inhibition in macrophages increases expression of the protumorigenic factor cyclooxygenase-2 (COX-2), and that COX-2 inhibition enhances responsiveness of tumors to ruxolitinib. These findings define a mechanism through which macrophages promote therapeutic resistance and highlight the importance of understanding the impact of targeted therapies on the tumor microenvironment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available